Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for IMVT-1402 in Myasthenia gravis. The expected timing is based on the latest available company guidance and may change.
05/20/26:- MG trial remains on track, with topline data expected in 2027. 08/06/26:- MG topline data remains expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.